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Nonlinear dynamics of cancer recurrence are known to be governed by several factors as initial tumour size, number of metastatic
sites, or quantity of drug resistant cells. The precise extent and location of tumours are very important factors so quantitative
and consistent methods of evaluation are needed to assess reponse to patient therapy. Whole-body 123I-metaiodobenzylguanidine
(mIBG) scintigraphy is used as primary medical image modality to detect neuroblastoma tumours due to its high specificity and
sensitivity. However, current oncological guidelines are based on qualitative observer-dependent analysis.This factmakes it difficult
to compare results of scintigraphies taken at different moments during therapy or at different institutions. In this paper, we review
analytical methods used in neuroblastoma detection and propose an observer-independent method to quantitatively analyse a
123I-mIBG scintigraphy.
1. Introduction
Nonlinear dynamics of cancer recurrence are governed by
a balance between several factors such as initial tumor
size, mutation rates, and growth kinetics of drug-sensitive
and resistance cells [1]. In recent years, there has been
an increasing interest for mathematical models in tumour
growth, by taking into account the temporal evolution which
can be controlled by slight changes in the sequence of tumour
images. Based on these images, many theoretical models have
been proposed [2–6].
Neuroblastoma is the third most common malignant
solid tumor of childhood. It is metastatic or with high
risk for recurrence in nearly 50% of cases [7]; therefore,
successful planning of individual patient therapy requires
precise delineation of the extent of the neuroblastoma.
Anatomic imaging methods, such as Computerized
Tomography (CT) and Magnetic Resonance Imaging (MRI),
are most useful for the evaluation of the primary tumor
mass and nearby involved lymph nodes. Functional imag-
ing radioactive tracers, such as 123𝐼-mIBG, 18𝐹-EDG, and
99
𝑚𝑇𝑐-MDP, are used to assess the extent of disease and to
search for distant metastases [8].
In particular, neuroblastoma’s cells take up and metabo-
lize norepinephrine, so its analogue metaiodobenzylguani-
dine (mIBG) is an ideal specific agent for imaging. 123𝐼-
mIBG is a gamma emitting radionuclide developed in the
early 1980s to visualise tumours [9]. 123𝐼-mIBG scintigraphy
has been in clinical use for more than 20 years for diagnostic
assessment. Current radiological guidelines for image acqui-
sition with 123𝐼-mIBG in [10] define that scanning is to be
performed 24 hours after its injection. A single or multiple
head gamma camera with a large field of view is necessary
to acquire planar images. The patient should be placed in the
supine position to perform a whole-body imaging. Gamma
camera scans the whole patient body counting gamma pho-
tons detected at each position. The scan produces a planar
image where each pixel’s intensity represents gamma photons
detected at this position in patient’s body so that white peaks
could be observed at patient’smIBGavid tissues (e.g., tumour,
metastases, etc.). Each whole-body scan includes two images,
the front and the rear scan of the patient’s body.
To date, radiological guidelines in [10] define a qualitative
interpretation criterion of image which has been defined
in terms of visual differences between pathological uptake
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pattern against physiological (normal) pattern. Following
these qualitative guidelines, physicians can perform a good
evaluation of a given image in terms of clear positive findings
or clear negative results. But they are unable to compare
results of a given scintigraphy with other previous ones to
evaluate the stage of disease when visual differences between
scans are not so evident.
A major drawback to the diagnosis of successive scans is
that they display variations in intensity, due to the difficulty
of maintaining the same exact conditions of the patient and
the gamma camera in every scanning session. This variation
in intensity is caused by changes in the accumulation of
radioisotopes during each examination, the image quality of
the gamma camera, the volume of water intake, the amount
of urine excreted, or the response to drug treatment of each
patient.
Current oncological studies [11] are focused on finding
some observer-independent method allowing of comparison
of the results between scintigraphies that may help to stratify
patient response to therapy. In this paper, we introduce
a simple procedure for quantitative observer-independent
measurement of uptake level in a single whole-body 123𝐼-
mIBG scintigraphy.
This paper is structured as follows. In Section 2, we detail
the proposed observer-independent measurement method.
Experimental results are provided in Section 3, and conclu-
sions are drawn in Section 4.
2. Materials and Methods
123
𝐼-mIBG scintigraphies were acquired in human studies by
NuclearMedicine Unit of Hospital La Fe following guidelines
described in [10] after a slow intravenous injection of 123𝐼-
mIBG (dose: 100 𝜇Ci/Kg) and using a scintillation camera set
to a photopeak equal to the principal gamma photon emitted,
that is, of 159KeV. Aminimum of 250,000 and amaximum of
500,000 photon counts were obtained for each front and rear
view.
The group ofmIBG scans from each patient were read in a
blinded fashion by two trained clinicians without knowledge
of the interpretation of the original report made by the
nuclear medicine physicians with good correlation.
Each scintigraphic image is a representation of the
radioactive distribution inside the body. Each pixel contains
a discrete value, which is related to the number of gamma
photons detected within the period of acquisition. These
discrete values follow a statistical Poisson distribution due to
the random nature of radioactive disintegration.
In other words, the number of discrete arrivals over a
period of time is not constant but is modelled by Poisson’s
equation as follows:
𝑃 (𝑋 = 𝑘) =
𝜇
𝑘
𝑒
−𝜇
𝑘!
, (1)
where 𝑃(𝑋 = 𝑘) is the probability that the number 𝑋 of
detected photons is equal to 𝑘 and 𝜇 is the mean value (which
is unknown) of the distribution.
This formula implies in daily nuclear medicine practice
that the number of photon counts has to be increased in order
to reduce the effect of Poisson noise. This can be achieved by
increasing the acquisition time, which increases the patient
motion and decreases camera throughput, or increasing the
amount of administered radioactive material, which will lead
to serious patient’s health problems. Given these limitations,
image processing techniques are needed to work without
increasing photon counts.
First attempts to quantify uptake in regions of interest
(ROI) in scintigraphies were made in 1973. In [12], an uptake
measurement of 99𝑚𝑇𝑐 in thyroid studies based on the
number of gamma photons detected (counts) was proposed.
The main idea was to calculate the ratio between counts in
ROI divided by the total body counts.
Heart-to-mediastinal (H/M) uptake ratio derived from
mIBG scintigraphy has been used as a quantitative measure-
ment of uptake with success to monitor response to medical
treatment in areas such as cardiac sympathetic imaging [13].
This measure of specific to nonspecific uptake is intrinsically
very simple: the ratio of the counts per pixel in two regions
of interest (ROIs), one drawn around the heart and the
other drawn in the midline upper thorax. This simplicity
has contributed to the widespread use of the H/M ratio
for comparing different populations. However, there is great
variation of H/M ratio among publications from various
institutions.
We propose also a very simple approach based on the
uptake ratio between neuroblastoma tumours and the rest
of tissues to standarize the measurement procedure and to
minimize variation in measurements between institutions.
Let us denote by 𝐼 the front (or rear) view of a whole-body
123
𝐼-mIBG scintigraphy of size 𝑚 × 𝑛 pixels. Let 𝑥𝑖𝑗 ∈ [0, 1]
be the intensity of pixel at coordinates (𝑖, 𝑗) in image 𝐼 that
represents radionuclide uptake by tissue (photon counts) at
these coordinates. Since we are interested in measuring the
uptake inside the patient’s body, wewill only take into account
the set 𝐼+ = {(𝑖, 𝑗) ∈ 𝐼 : 𝑥
𝑖𝑗
> 0}.
And let 𝐼 and 𝜎
𝐼
be the mean and the standard deviation
of intensity in 𝐼, given, respectively, by (2) and (3) as
𝐼 =
∑
(𝑖,𝑗)∈𝐼
+ 𝑥𝑖𝑗
# {𝐼+}
, (2)
𝜎
𝐼
= √
1
# {𝐼+}
∑
(𝑖,𝑗)∈𝐼
+
(𝑥
𝑖𝑗
− 𝐼)
2
. (3)
In order to be able to compare the uptake value 𝑥
𝑖𝑗
at
pixel (𝑖, 𝑗) with uptake value 𝑥󸀠
𝑖𝑗
at the same patient’s body
coordinates in another scintigraphy, we need both values to
be transformed into the same normalized scale.
We will transform the intensity level at each pixel 𝑥
𝑖𝑗
into
its normalized uptake value 𝑈
𝐼
(𝑖, 𝑗) with (4) as
𝑈
𝐼
(𝑖, 𝑗) = max(
𝑥
𝑖𝑗
− 𝐼
𝜎
𝐼
, 0) , (4)
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Table 1: 𝑈
𝐼
(background) and measurements of regions of interest at a series of five scintigraphies from 𝑇
1
to 𝑇
5
of patient P4 (Figure 1).
Regions 𝑇
1
𝑇
2
𝑇
3
𝑇
4
𝑇
5
𝑈
𝐼
(background) 0,25 0,22 0,26 0,3 0,29
𝑈
𝐼
(Right Femur) 0,3 0,27 1,01 1,6 1,44
𝑈
𝐼
(Liver) 1,43 1,35 1,3 1,39 0,94
𝑈
𝐼
(Left Tumor) 1,3 0,22 0,26 0,3 0,29
𝑈
𝐼
(Right Tumor) 1,35 0,22 2,4 1,68 2,35
and we call it the normalized uptake value at coordinates
(𝑖, 𝑗) referenced to 𝐼. Notice that we are only interested in
measuring those𝑥
𝑖𝑗
values that are greater than 𝐼because they
are the relevant uptake points. Uptake at 𝑥
𝑖𝑗
values lower than
𝐼 has a value of 𝑈
𝐼
(𝑖, 𝑗) = 0.
Once every pixel in scintigraphy is transformed into its
normalized uptake value based on its standard deviation from
mean 𝐼, we are able to takemeasurements that are comparable
with the next scintigraphies of the same patient.
When measuring uptake at any body point, image is
quantified by areas, but not by pixels. A single pixel may have
a high scintigraphy value, but it is not taken into account
because noise exists in the original image.
For noise reduction, we need to replace raw counts at
region with processed counts having reduced noise. This can
be achieved by smoothing counts over neighboring pixels.
The smoothed area is a weighted average, in which raw counts
at point 𝑅
𝑗
are replaced by processed counts 𝑄
𝑖
given by (5)
where the weights 𝑤
𝑖𝑗
are chosen to provide a smoothing
scheme and are normalized by the sum rule in (6) as
𝑄
𝑖
= ∑
𝑗
𝑤
𝑖𝑗
𝑅
𝑗
, (5)
∑
𝑗
𝑤
𝑖
≡ 1 ∀𝑖. (6)
Therefore, when measuring any image region of interest
ROI
𝑘
(e.g., liver, tumour, etc.), we will use weights equal to
1/𝑘 where 𝑘 is the number of pixels in the region. Then the
uptake measurement, 𝑈
𝐼
(ROI
𝑘
), of any region of interest is
defined as the average of the positive normalized uptakes at
(𝑖, 𝑗) ∈ ROI
𝑘
; that is,
𝑈
𝐼
(ROI
𝑘
) =
∑ {𝑈
𝐼
(𝑖, 𝑗) : (𝑖, 𝑗) ∈ ROI}
# {ROI}
. (7)
3. Results and Discussion
We took measurements in a test set of whole-body 123𝐼-
mIBG scintigraphies of annoymous patients. This experi-
mental set contains 23 whole-body 123𝐼-mIBG scintigraphies
belonging to 19 children under 14 labeled patients from P1
to P19 suffering from neuroblastoma taken with different
gamma cameras.
Figure 1: A series of five original rear view 123𝐼-mIBG test samples
of patient P4 from 𝐼P4𝑇
1
to 𝐼P4𝑇
5
with diagnosed tumour areas
selected inside circles.
Wewere interested in calculating the uptake present at the
whole patient’s body frame which we call 𝑈
𝐼
(background)
and is defined as follows:
𝑈
𝐼
(background) =
∑ {𝑈
𝐼
(𝑖, 𝑗) : (𝑖, 𝑗) ∈ 𝐼
+
}
# {𝐼+}
. (8)
At every whole-body scintigraphy in test set, physicians
labeled each tumour region 𝑅
𝑘
in each view (rear and front)
and measured 𝑈
𝐼
(𝑅
𝑘
) with (7) applied to tumour pixels of
each 𝑅
𝑘
. In case a tumour was visible in both views, it had
two measurements, the 𝑈
𝐼
(𝑅
𝑘
) referenced to 𝐼 of the front
view and another measurement in the rear view.
We also calculated the whole-body 𝐼 background uptake
mean𝑈
𝐼
(background) in both views (rear and front) with (8)
and 𝑈
𝐼
(liver).
A comparison of the measurement results of P4 patient’s
123
𝐼-mIBGs (only the rear view for simplicity) is shown in
Figure 2 andTable 1 where wemay appreciate that there exists
a threshold of reference at𝑈
𝐼
(background) that remains close
to 0.3 in all five P4 scintigraphies, mainly in 𝑇
4
and 𝑇
5
.
Relation between 𝑈
𝐼
(background) and each 𝑈
𝐼
(tumour)
may be used as an evidence of tumour uptake evolution. Fur-
thermore,𝑈
𝐼
(background) values at both views are similar in
all the P4 patient’s mIBGs.
In Figure 3 and Table 2, evolution of 𝑈
𝐼
(background)
values in scintigraphies 𝑇
1
and 𝑇
2
is consecutive in time
of patients P4, P10, P11, and P16. In all four patients,
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Figure 2: Evolution of 𝑈
𝐼
(regions) at tumour regions and
𝑈
𝐼
(background).
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Figure 3: Evolution of 𝑈
𝐼
(background) values in front views of
scintigraphies 𝑇
1
and 𝑇
2
consecutive in time of patients P4, P10, P11,
and P16.
Table 2:𝑈
𝐼
(background) at scintigraphies 𝑇
1
and 𝑇
2
of patients P4,
P10, P11, and P16.
𝑈
𝐼
(background) 𝑇
1
𝑇
2
P4 0,25 0,22
P10 0,2816 0,271
P11 0,2727 0,337
P16 0,3072 0,3034
𝑈
𝐼𝑇
2
(background) of 𝑇
2
scintigraphy is close to
𝑈
𝐼𝑇
1
(background) of previous scintigraphy 𝑇
1
, specially
in patients P10 and P16. 𝑈
𝐼
(background) may be used as a
threshold of reference to compare results.
Comparison between all patients’ results is shown in
Figure 4. We show in red squares 𝑈
𝐼
(background) of rear
0
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0 5 10 15 20 25 30 35 40
Uptake areas
Total body background
Figure 4: Comparison between all patients’ results. In red squares,
𝑈
𝐼
(background) of front and rear views of each scintigraphy of each
patient and in blue diamonds𝑈
𝐼
(informed tumours) and𝑈
𝐼
(livers).
and front views of the scintigraphies of each patient and in
blue diamonds𝑈
𝐼
(informed tumours) and𝑈
𝐼
(livers). In the
whole test set, 𝑈
𝐼
(background) remains close to 0.3, in both
rear and front views, that will allow us to compare results
between different patients.
4. Conclusions
A simple observer-independent method for measuring the
uptake level of 123𝐼-mIBG in any body region of children
has been presented.This technique enables us to measure the
relative amount of uptake with a quantitative and objective
unit based on standard deviation of the uptake area. The
lesion grey level is used as an uptake measurement evidence.
Any region of interest could bemeasured in any other patient
and compared with the estimated normal grey level. The
larger the standard deviation value of grey level is at a given
region, the greater the possibility of tumour existence is.
Preliminary results in test set show that the relationship
between the background uptake mean and the tumours
uptake mean may be used as evidence of a patient’s tumours
uptake evolution due to the fact that background uptake
mean tends to be constant in every analysed 123𝐼-mIBG
scintigraphy of the same patient at both rear and front views.
Moreover, the results of the whole-body background
uptake mean obtained at rear and front views are similar in
thewhole test set, even though different gamma cameraswere
used on different patients and years. This indicates that the
method may be useful to compare results between different
patients and even between different medical institutions.
These quantitative measurements add more descriptive
information of tumours that may be included in models of
nonlinear dynamics of cancer recurrence to study correlation
between uptake and tumour relapse.
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